HomeDalfampridineDalfampridine + Dolutegravir Sodium And Rilpivirine Hydrochloride

Does Dalfampridine Interact with Dolutegravir Sodium And Rilpivirine Hydrochloride?

Dalfampridine and Dolutegravir Sodium And Rilpivirine Hydrochloride have a contraindicated drug interaction according to U.S. FDA drug labeling data. Dolutegravir inhibits OCT2 and MATE1, increasing dalfampridine plasma concentrations. Consider alternatives due to risk of Torsade de Pointes. The mechanism involves inhibition of renal organic cation transporter 2 (oct2) and multidrug and toxin extrusion transporter 1 (mate1). Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Dalfampridine Class
Potassium Channel Blocker
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Dalfampridine and Dolutegravir Sodium And Rilpivirine Hydrochloride occurs because inhibition of renal organic cation transporter 2 (oct2) and multidrug and toxin extrusion transporter 1 (mate1). Clinically, this means dolutegravir inhibits oct2 and mate1, increasing dalfampridine plasma concentrations. consider alternatives due to risk of torsade de pointes. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Dalfampridine and your doctor is considering prescribing Dolutegravir Sodium And Rilpivirine Hydrochloride (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dalfampridine(Ampyra)+💊 Dolutegravir Sodium And Rilpivirine Hydrochloride(Juluca)

Severity & Interaction Details

contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Potassium Channel Blocker
Drug B class
Source
NLP:dolutegravir sodium and rilpivirine hydrochloride

What this means in plain English

Dolutegravir inhibits OCT2 and MATE1, increasing dalfampridine plasma concentrations. Consider alternatives due to risk of Torsade de Pointes.

About Dalfampridine and Dolutegravir Sodium And Rilpivirine Hydrochloride

Dalfampridine is a Potassium Channel Blocker. You may recognize them by the brand names Ampyra and Juluca. Both medications are taken by mouth.

What the FDA label says

"Inhibition of renal organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE1)"

📖 Source: NLP:dolutegravir sodium and rilpivirine hydrochloride

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Dalfampridine and Dolutegravir Sodium And Rilpivirine Hydrochloride against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.